Borderline resectable hepatocellular carcinoma: Definitions, efficacy and safety results from a prospective phase Ib/II study evaluating camrelizumab plus lenvatinib combined with TACE as preoperative therapy (BRHCC)

被引：0
|
作者：
Liao, M. [1 ]
Yang, Y. [2 ,5 ]
Jiang, H. [3 ]
Huang, J. [1 ]
Liu, C. [4 ]
Yang, Y. [2 ,5 ]
Xie, K. [6 ]
Luo, X. [7 ]
Zhou, J. [1 ]
Wang, X. [8 ]
Wu, H.
Zeng, Y. [9 ]
Li, Q. [5 ]
机构：
[1] Sichuan Univ, West China Hosp, Div Liver Surg, Dept Gen Surg & Lab Liver Surg, Chengdu, Peoples R China
[2] Sichuan Univ, West China Hosp, Ctr Canc, Chengdu, Peoples R China
[3] Sichuan Univ, West China Hosp, Dept Radiol, Chengdu, Peoples R China
[4] Sichuan Univ, West China Hosp, Div Liver Surg, Dept Gen Surg, Chengdu, Peoples R China
[5] Sichuan Univ, West China Hosp, Dept Med Oncol, Ctr Canc, Chengdu, Peoples R China
[6] Sichuan Univ, West China Hosp, Liver Transplant Ctr, Chengdu, Peoples R China
[7] Sichuan Univ, West China Hosp, Dept Gastroenterol & Hepatol, Chengdu, Peoples R China
[8] Sichuan Univ, West China Hosp, Div Abdominal Tumor Multimodal Treatment, Dept Radiat Oncol, Chengdu, Peoples R China
[9] Sichuan Univ, West China Hosp, Div Liver Surg, Dept Gen Surg & Lab Liver Surg, Chengdu, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
基金：
中国博士后科学基金;
关键词：
D O I：
10.1016/j.annonc.2024.08.1026
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
966P
引用
收藏
页码：S664 / S665
页数：2
相关论文
共 50 条
  • [1] TACE combined Lenvatinib plus Camrelizumab versus TACE alone in efficacy and safety for unresectable hepatocellular carcinoma: a propensity score-matching study
    Tang, Zhihong
    Bai, Tao
    Wei, Tao
    Wang, Xiaobo
    Chen, Jie
    Ye, Jiazhou
    Li, Shangqi
    Wei, Meng
    Li, Xingzhi
    Lin, Youzhi
    Tang, Juan
    Li, Lequn
    Wu, Feixiang
    BMC CANCER, 2024, 24 (01)
  • [2] Preliminary efficacy and safety of perioperative treatment of camrelizumab combined with apatinib in resectable hepatocellular carcinoma (HCC): A prospective phase II study.
    Xia, Yongxiang
    Wang, Ping
    Pu, Liyong
    Qian, Xiaofeng
    Cheng, Feng
    Wang, Ke
    Zhang, Chuanyong
    Li, Donghua
    Li, Xiangcheng
    Zhang, Feng
    Zhao, Jie
    Li, Si
    Xi, Wenjing
    Wang, Xuehao
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [3] Efficacy and Safety of TACE Combined With Lenvatinib Plus PD-1 Inhibitors Compared With TACE Alone for Unresectable Hepatocellular Carcinoma Patients: A Prospective Cohort Study
    Qu, Shuping
    Zhang, Xiaobing
    Wu, Yutian
    Meng, Yan
    Pan, Hongyu
    Fang, Qiang
    Hu, Lei
    Zhang, Jin
    Wang, Ruoyu
    Wei, Lixin
    Wu, Dong
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [4] Preliminary data of a phase Ib/II trial evaluating the efficacy and safety of adebrelimab, camrelizumab plus apatinib as first-line therapy in patients with advanced hepatocellular carcinoma
    Long, Yin
    Yang, Qiong
    Huang, Ziqi
    He, Xiaodong
    Huang, Jue
    Liao, Jianguo
    Chen, Yajin
    Hu, Hai
    Zhang, Lei
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [5] Efficacy and Safety of TACE Combined with Regorafenib versus TACE Combined with Camrelizumab in Hepatocellular Carcinoma With Untreatable Progression After TACE Combined with Sorafenib Therapy: A Case Control Study
    Ren, Yanqiao
    Liu, Yiming
    Song, Songlin
    Zheng, Chuansheng
    CANCER CONTROL, 2024, 31
  • [6] Efficacy and safety of envafolimab plus lenvatinib combined with TACE in initially unresectable hepatocellular carcinoma: An open-label, single-arm, phase II study
    Bai, Xueli
    Chen, Yiwen
    Zhang, Junlei
    Hu, Wendi
    Li, Xiang
    Shen, Yan
    Zhang, Min
    Wu, Jian
    Gao, Shunliang
    Yu, Jun
    Que, Risheng
    Zhang, Yun
    Yang, Fuchun
    Xia, Weiliang
    Zhang, Aibin
    Tang, Xiaofeng
    Liang, Tingbo
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [7] A phase Ib/II, open-label study evaluating the efficacy and safety of Toripalimab injection (JS']JS001) or combination with Lenvatinib as a neoadjuvant therapy for patients with resectable hepatocellular carcinoma (HCC).
    Shi, Ying-Hong
    Ji, Yuan
    Liu, Wei-Ren
    Pang, Yan-Rui
    Ding, Zhen-Bin
    Fu, Xiu-Tao
    Zhang, Xin
    Huang, Cheng
    Sun, Yun-Fan
    Zhu, Xiao-Dong
    Sun, Hui-Chuan
    Zhou, Jian
    Fan, Jia
    CANCER RESEARCH, 2021, 81 (13)
  • [8] Efficacy, safety, and biomarker analysis of TACE combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a real-world study
    Meng, Lingzhan
    Li, Hu
    Ji, Yingjie
    Yu, Peng
    Wang, Zizheng
    Cao, Li
    Shi, Bin
    Shao, Yanling
    Yan, Jin
    Gao, Yinjie
    Zhu, Zhenyu
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2024, 74 (01)
  • [9] Safety and efficacy of lenvatinib combined with camrelizumab plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: A two-center retrospective study
    Sun, Bo
    Zhang, Lijie
    Sun, Tao
    Ren, Yanqiao
    Cao, Yanyan
    Zhang, Weihua
    Zhu, Licheng
    Guo, Yusheng
    Gui, Yuxi
    Liu, Fengyong
    Chen, Lei
    Xiong, Fu
    Zheng, Chuansheng
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [10] Updated efficacy and safety results from the phase Ib/II study of surufatinib combined with camrelizumab and chemotherapy in patients with advanced colorectal cancer
    Li, Sheng
    Zhu, Liangjun
    Li, Xiaoyou
    Huang, Jiayuan
    Bao, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345